Actelion buyout could reach $9.8B, Bloomberg figures

Bloomberg sat down to crunch the numbers on a potential takeover of Switzerland's Actelion and concluded that the biotech could fetch around $9.8 billion if Amgen ($AMGN) or some other suitor swoops in to take it over. Report

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.